Etoricoxib in Patients With Parkinsonian Disease
Recruiting · NCT07370532 · Interventional (participants receive a specific treatment) · Lead sponsor: Ihab Elsayed Hassan
View the official record on ClinicalTrials.gov →Interventions studied
EtoricoxibL-dopa
What this trial is about
Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).
Who can take part
Age range
50 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥ 18 years.
- Both male and female will be included.
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Exclusion criteria
- Breast feeding
- Patients with significant liver and kidney function abnormalities.
- Alcohol and / or drug abusers.
- Patients with known allergy to the study medications
- Pregnant women and women with planned pregnancy.
- Patients who are currently using other anti-inflammatory drugs.
Where it is running
1 location listed.
- Mansoura University - Al Mansurah, Egypt